PR Newswire PharmaOriginal article
HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell
Phase 1positiveKMCAR™ T-CellPositive
AI Analysis
Summary
HaemaLogiX announced the first patient has been successfully dosed with KMCAR™ T-cell therapy in the Phase 1 KOALA trial for relapsed/refractory kappa-restricted multiple myeloma, with treatment reported as well tolerated.
Clinical Trial Data
Phase
Phase 1
Patients
1
Outcome Details
First patient successfully dosed and treatment well tolerated
Importance:5/10
Sentiment:
0.75
cell therapymultiple myelomaPhase 1first patient dosedKOALA trial
Related Companies
Read the original article
Published by PR Newswire Pharma on August 26, 2026 11:00 AM